These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 1881606)

  • 1. Discrimination of tetrahydroaminoacridine responders by a single dose pharmaco-EEG in patients with Alzheimer's disease.
    Alhainen K; Partanen J; Reinikainen K; Laulumaa V; Soininen H; Airaksinen M; Riekkinen P
    Neurosci Lett; 1991 Jun; 127(1):113-6. PubMed ID: 1881606
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmaco-EEG test dose response predicts cholinesterase inhibitor treatment outcome in Alzheimer's disease.
    Knott V; Mohr E; Mahoney C; Ilivitsky V
    Methods Find Exp Clin Pharmacol; 2000 Mar; 22(2):115-22. PubMed ID: 10849895
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term tetrahydroaminoacridine treatment and quantitative EEG in Alzheimer's disease.
    Kogan EA; Verchovsky RG; Neufeld MY; Klimovitsky SSh; Treves TA; Korczyn AD
    J Neural Transm Suppl; 2007; (72):203-6. PubMed ID: 17982896
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Physostigmine and tetrahydroaminoacridine treatment of Alzheimer's disease.
    Gustafson L
    Acta Neurol Scand Suppl; 1993; 149(Rand):39-41. PubMed ID: 8128836
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Psychometric discrimination of tetrahydroaminoacridine responders in Alzheimer patients.
    Alhainen K; Helkala EL; Riekkinen P
    Dementia; 1993; 4(1):54-8. PubMed ID: 8358507
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Responder characteristics to a single oral dose of cholinesterase inhibitor: a double-blind placebo-controlled study with tacrine in Alzheimer patients.
    Almkvist O; Jelic V; Amberla K; Hellström-Lindahl E; Meurling L; Nordberg A
    Dement Geriatr Cogn Disord; 2001; 12(1):22-32. PubMed ID: 11125238
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oral tetrahydroaminoacridine treatment of Alzheimer's disease evaluated clinically and by regional cerebral blood flow and EEG.
    Minthon L; Gustafson L; Dalfelt G; Hagberg B; Nilsson K; Risberg J; Rosén I; Seiving B; Wendt PE
    Dementia; 1993; 4(1):32-42. PubMed ID: 8358504
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hippocampal atrophy, acute THA treatment and memory in Alzheimer's disease.
    Riekkinen P; Soininen H; Helkala EL; Partanen K; Laakso M; Vanhanen M; Riekkinen P
    Neuroreport; 1995 Jun; 6(9):1297-300. PubMed ID: 7669991
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Somatostatin and cognitive functions in Alzheimer's disease--the relationship of cerebrospinal fluid somatostatin increase with clinical response to tetrahydroaminoacridine.
    Alhainen K; Sirviö J; Helkala EL; Reinikainen K; Riekkinen P
    Neurosci Lett; 1991 Sep; 130(1):46-8. PubMed ID: 1684233
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tacrine (tetrahydroaminoacridine; THA) and lecithin in senile dementia of the Alzheimer type: a multicentre trial. Groupe Français d'Etude de la Tetrahydroaminoacridine.
    Chatellier G; Lacomblez L
    BMJ; 1990 Feb; 300(6723):495-9. PubMed ID: 2107926
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Discrimination of Alzheimer patients responding to cholinesterase inhibitor therapy.
    Alhainen K; Riekkinen PJ
    Acta Neurol Scand Suppl; 1993; 149():16-21. PubMed ID: 7907454
    [TBL] [Abstract][Full Text] [Related]  

  • 12. EEG regional changes during long-term treatment with tetrahydroaminoacridine (THA) in Alzheimer's disease.
    Shigeta M; Persson A; Viitanen M; Winblad B; Nordberg A
    Acta Neurol Scand Suppl; 1993; 149():58-61. PubMed ID: 8128842
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Longitudinal changes in quantitative EEG during long-term tacrine treatment of patients with Alzheimer's disease.
    Jelic V; Dierks T; Amberla K; Almkvist O; Winblad B; Nordberg A
    Neurosci Lett; 1998 Sep; 254(2):85-8. PubMed ID: 9779926
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Frontal dysfunction blocks the therapeutic effect of THA on attention in Alzheimer's disease.
    Riekkinen P; Riekkinen M; Soininen H; Kuikka J; Laakso M; Riekkinen P
    Neuroreport; 1997 May; 8(8):1845-9. PubMed ID: 9223063
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tetrahydroaminoacridine (THA) in Alzheimer's disease.
    Byrne J; Arie T
    BMJ; 1989 Apr; 298(6677):845-6. PubMed ID: 2497817
    [No Abstract]   [Full Text] [Related]  

  • 16. Acute nicotine effects on auditory sensory memory in tacrine-treated and nontreated patients with Alzheimer's disease: an event-related potential study.
    Engeland C; Mahoney C; Mohr E; Ilivitsky V; Knott VJ
    Pharmacol Biochem Behav; 2002 May; 72(1-2):457-64. PubMed ID: 11900820
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of tetrahydroaminoacridine on liver function in patients with Alzheimer's disease.
    O'Brien JT; Eagger S; Levy R
    Age Ageing; 1991 Mar; 20(2):129-31. PubMed ID: 2053502
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tetrahydroaminoacridine improves the recency effect in Alzheimer's disease.
    Riekkinen M; Soininen H; Riekkinen P; Kuikka J; Laakso M; Helkala EL; Partanen J; Riekkinen P
    Neuroscience; 1998 Mar; 83(2):471-9. PubMed ID: 9460755
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of tetrahydroaminoacridine on cognition, function and behaviour in Alzheimer's disease.
    Molloy DW; Guyatt GH; Wilson DB; Duke R; Rees L; Singer J
    CMAJ; 1991 Jan; 144(1):29-34. PubMed ID: 1984813
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical pharmacology of tetrahydroaminoacridine: a possible therapeutic agent Alzheimer's disease.
    Kumar V; Becker RE
    Int J Clin Pharmacol Ther Toxicol; 1989 Oct; 27(10):478-85. PubMed ID: 2684868
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.